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Background: Tumor cells killed by radiation therapy (RT) are a potentially good source of antigens for dendritic cell
(DC) uptake and presentation to T-cells. RT upregulates cell death receptors such as Fas/CD95 and MHC-I, induces
the expression of co-stimulatory molecules on tumor cells, and promotes production of pro-inflammatory cytokines.
High-dose interleukin-2 (HD-IL-2) bolus has been shown to obtain objective response rates ranging from 15% to
17% in patients with metastatic melanoma or renal cell carcinoma (RCC), with 6% to 8% of cases experiencing a
durable complete response. However, HD-IL-2 is also associated with severe side-effects; if it is to remain a component
of the curative treatment strategy in patients with metastatic melanoma or RCC, its therapeutic efficacy must be
improved and patients who are most likely to benefit from treatment must be identified a priori. We designed a
clinical study combining immunomodulating RT and HD-IL-2 to evaluate their clinical and immunological efficacy
and to explore the predictive and prognostic value of 1) tumor-specific immune response and 2) serum levels of
proangiogenic cytokines.
Methods/design: The primary endpoint of this proof-of-principle phase II study is immune response. Secondary
endpoints are the identification of biomarkers potentially predictive of response, toxicity, response rate and overall
survival. Three daily doses of booster radiotherapy (XRT) at 6–12 Gy will be administered to at least one metastatic
field on days −3 to −1 before the first and third cycle. Treatment with IL-2 (dose 18 MIU/m2/day by continuous IV
infusion for 72 hours) will start on day +1 and will be repeated every 3 weeks for up to 4 cycles and then every
4 weeks for a further 2 cycles. Immune response against tumor antigens expressed by melanoma and/or RCC will be
evaluated during treatment. Circulating immune effectors and regulators, e.g. cytotoxic T lymphocytes and regulatory
T cells, as well as serum levels of proangiogenic/proinflammatory cytokines will also be quantified.
Discussion: This study aims to evaluate the potential immunological synergism between HD-IL-2 and XRT, and to identify
biomarkers that are predictive of response to IL-2 in order to spare potentially non responding patients from toxicity.
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The concept that the immune system can distinguish
the neoplastic from the normal self was proposed almost
a century ago. Both cellular and humoral antitumor im-
mune responses to tumor-associated antigens (TAAs)
have been observed in many cancer patients. Tumors
are genetically unstable, and the emergence of new
genetic variants ensures that tumors survive in spite
of the host’s immune system. Tumor development in-
volves a prolonged series of checks and balances be-
tween the host, attempting to curtail tumor growth,
and the tumor, benefitting from genetic changes, al-
tering the microenvironment and avoiding immune
elimination. Within this context, the “immunoediting
hypothesis” suggests that the host’s immune system is
capable of edit for the survival of tumors that become
resistant to immune cells by eliminating cancer cells
sensitive to immune attack [1-5].
Ionizing radiation therapy (RT) is known to kill cancer
cells and other cells within the tumor stroma, including
endothelial cells and intratumoral lymphocytes. The cell
surface translocation of calreticulin or the extracellular
release of high-mobility group protein B1 (HMGB1,a
nonhistone nuclear protein), are among the molecular
signals required to have an “immunogenic cell death”.
Ionizing radiation may induce these changes and pro-
mote immunogenic cell death, favoring the development
of an effective immune response [6-8]. Tumor cells
killed by RT should, in theory, be a very good source of
antigens for dendritic cell (DC) uptake and presentation
of T cells [9,10]. The optimal activation of T cells by DC
can only be achieved in the presence of inflammatory or
“danger” signals. Although these danger signals can be
generated by radiation exposure, their nature remains
largely undefined [11]. Proinflammatory cytokines IL-1β
and TNF-α can also be induced by radiation [12,13]. In
addition, RT can upregulate cell death receptors such as
Fas/CD95 and MHC-I and costimulate specific tumor
cells, enhancing their tendency to either die or be recog-
nized [14,15]. Finally, RT has complex effects on the
tumor microenvironment: in particular, radiation-induced
inflammatory signals, changes in extracellular matrix
proteins, and the expression of adhesion molecules by
endothelial cells of tumor vessels all facilitate the hom-
ing of both antigen-presenting and effector T cells to
the tumor [16-18].
Demaria et al. recently showed in a murine model that
irradiation of a grafted tumor generated an immune
response against tumor cells and that this immune re-
sponse inhibited the growth of tumor grafted outside the
irradiation field. This anti-tumor effect was hypothesized
to be the result of a specific immune response as it was
not observed in immunodeficient mice (T-cell deficient,
nude mice), was tumor-type specific (growth of a secondgraft of a different cell line was not affected by irradi-
ation of the first graft), and synergized with administra-
tion of the FMS-like tyrosine kinase 3 (Flt-3) ligand.
Indeed, the use of Flt-3 alone had no influence on the
second graft, suggesting that the effect was not due to
an unspecific boost of immunity induced by the Flt-3
ligand, but rather to the amplification of a tumor-
specific response induced by the tumor irradiation.
These data indicate that radiotherapy can prime the im-
mune system against similar cells some distance away
from the irradiation field (abscopal effect) and that, in
the absence of an additional immune system stimulation,
the radiation-induced immune response has no clinical
effect [19-21]. However, optimal radiation regimens have
yet to be defined. Formenti et al. compared different ra-
diation regimens in combination with anti-CTLA-4 and
found that a hypofractionated regimen (8 Gyx3) was
more effective than a single dose of 20 Gy [8].
High-dose interleukin-2 (HD-IL-2) has been reported
to induce an objective clinical disease regression in 15 to
17% of patients with metastatic melanoma and renal cell
carcinoma, with 6% to 8% of cases experiencing a dur-
able complete response of all metastases [22-24]. The
first role attributed to IL-2 was its potent capacity to en-
hance in vitro T-cell proliferation and differentiation,
and for this reason it was originally named T-cell growth
factor. Following these initial descriptions of IL-2 func-
tion, a number of studies highlighted numerous contra-
dictory functions of the cytokine. There is also evidence
that IL-2 is an important factor in the generation of
memory T-cells which undergo secondary expansion
when they re-encounter an antigen. However, in contrast
to these immune-enhancing functions, IL-2 also pro-
motes activation-induced cell death (AICD) of T-cells
and has anti-inflammatory properties [25].
Analogously to IFN-gamma, IL-2 limits IL-17 produc-
tion and exerts its immunosuppressive function by
stimulating the generation and homeostasis of regulatory
T cells (Tregs) [26]. In fact, IL-2 is known to be a non-
redundant factor in the in vivo homeostasis of Tregs
which constitute a fundamental part of immunological
self-tolerance and immune regulation [25]. IL-2 eradica-
tion of tumors is thought to be mediated by enhanced
T-cell function and increased T-cell numbers. Lympho-
poiesis is partially driven by lymphopenia and homeo-
static proliferation. During homeostatic recovery, even
in the absence of antigen stimulus, lymphocyte subpopu-
lations shift, favoring antigen-experienced memory phe-
notypes and enhanced effector cell function. However,
although the antitumor effect of HD-IL-2 is not com-
pletely understood, it appears to induce the release of
proinflammatory cytokines into the blood and at the
tumor site, enabling the ingress of inflammatory cells
and promoting the cytolytic- and cytokine-producing
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the activation of monocytes/macrophages and other
tumor-infiltrating immune cells, recruits immune cells
from the periphery and triggers so-called epitope spreading,
with novel determinants recognized in the context of
the emergent immune response. HD-IL-2 suppresses
CD4 + CD25hi-FoxP3+ T-regulatory cells, the prime
contact-dependent suppressors of antigen-specific T cell
response in metastatic melanoma patients, with a demon-
strable clinical benefit.
Clinical evidence for an immune-mediated HD-IL-2
mechanism of action is based on tumor regression,
the development of organ-specific autoimmunity in
responders such as delayed-onset vitiligo, observed in
some of our patients, and the onset of autoimmune thy-
roiditis. Thyroiditis was the first autoimmune disease re-
ported to be induced by HD-IL-2 and which correlated
with a favorable clinical outcome. As interleukin-2 para-
doxically affects both tolerance and immunity in the ab-
sence of T-regulatory cells, HD-IL-2 increases effector
CD8+ cytotoxic function which is responsible for both
autoimmunity and tumor regression. Cancer immuno-
therapy with IL-2 has the potential to cure a subset of
patients who need to be identified before treatment
in order to minimize toxicity and improve therapeutic
index [25,27,28].
Prospective clinical trials have reported a response rate
of around 16% for melanoma patients treated with IL-2.
Data suggest that higher rather than lower dose regi-
mens are more likely to induce tumor regression in both
melanoma and RCC. A retrospective analysis of 270 pa-
tients with metastatic melanoma treated with HD-IL-2
between 1985 and 1993 reported objective response
rates of 16%, including a complete response rate of 6%.
The median response duration was 6.5 months, and
60% of complete responders were progression-free after
5 years [29]. A major difference between the HD bolus
IL-2 regimen and other chemotherapeutic melanoma
therapies lies in the duration and quality of the re-
sponses obtained. Of the 24 patients receiving HD-IL-2
regimens at the National Cancer Institute who experi-
enced a complete response (CR), 19 remained in complete
remission for 46 to 137 months. In the past, several
studies have focused on IL-2/chemotherapy combina-
tions in metastatic melanoma. Although randomized
trials have not been conducted to date, the HD-IL-2
bolus (600,000 to 720,000 U/kg intravenous (IV) every
8 hours for 15 doses) administered in the original NCI
studies would seem to be superior to continuous IV in-
fusion IL-2 [30]. Although response rates are compar-
able, they tend to be of shorter duration. In 7 published
studies on metastatic RCC, objective responses (OR),
complete responses (CR) and partial responses (PR) were
seen in 15, 7, and 8% of patients, respectively. Furthermore,the median duration of response was 54 months for all
responders, 20 months for PRs, and was not reached
for CRs. The median survival was 16 months for all
255 patients [31]. However, HD-IL-2 administration is
associated with numerous side-effects may thus have an
impact on every organ system in the body. In fact,
there is substantial variation in the toxicities experi-
enced by patients receiving high-dose IL-2 which are
thought to result primarily from capillary leak syn-
drome (CLS) and lymphoid infiltration, the latter ob-
served histologically in many organs [32,33]. Sondel
et al. studied continuous IL-2 infusion for 4–7 days at a
dose of approximately 9 MIU/m2/day [34]. In addition,
Dillman et al. demonstrated the efficacy of a higher dose
continuous infusion IL-2 regimen (18 MIU/m2/day) over
5 days during which CLS proved to be the limiting tox-
icity [35]. The same group studied a 96-hour continuous
infusion regimen for melanoma patients, reporting that it
was better tolerated, with no decrease in response rate
[36]. Continuous infusion may be more beneficial than
bolus dosing in terms of inducing a higher degree of
LAK cytotoxicity and higher rebound lymphocytosis. For
these reasons, Quan et al. used the 72-hour high-dose
continuous infusion schedule more frequently, reporting
good tolerance and activity in both melanoma and renal
cell carcinoma [37]. In an attempt to reduce the severity
of CLS, Rosenberg’s group used concomitant corticoster-
oid infusion during IL-2 therapy, observing that the cyto-
toxic function of CD8 + T lymphocytes was not affected
and that side-effects were reduced [38]. It is clear that, if
HD-IL-2 is to remain a component of a curative treat-
ment strategy in patients with metastatic melanoma or
RCC, its therapeutic index will have to be improved.
Two active areas of investigation within the field of
immunotherapy focus on the elimination of immune
suppression/regulation and the improvement of patient
selection.
Based on an understanding of the mechanisms of ac-
tion of IL-2, biomarkers of response to this cytokine
might allow us to identify a subset of patients who could
potentially benefit from treatment. To date, the majority
of putative predictors of IL-2 response have been post-
treatment variables, such as the height of rebound lym-
phocytosis, treatment-induced thrombocytopenia, the
development of autoimmune thyroiditis and vitiligo, and
the decrease in the absolute number and frequency of
peripheral Tregs.
In renal cell carcinoma, the level of carbonic anhy-
drase IX (CAIX) in primary tumors has been found
to be a potentially useful pretreatment predictor. In
both melanoma and RCC, serum vascular endothelium
growth factor (VEGF) and fibronectin have also been
identified as independent predictors of non response,
and high levels of these proteins have been correlated
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survival. Other analyses of pretreatment factors have
correlated IL-2 with the Cw7 phenotype or low serum
levels of IL-6 and C-reactive protein, but none has
proven to be sufficiently predictive of clinical benefit to
be useful in patient selection for IL-2 therapy [39-44].
Methods/design
Objectives
This is a proof-of-principle phase II study to assess
1) immune response and 2) potential biomarkers pre-
dictive of response to treatment with HD-IL-2.
Primary objective
The primary objective of this study is to determine the
immunological efficacy of the combined RT/HD-IL-2
treatment (assessed by IFN-g ELISPOT analysis) in
terms of its ability to enhance the proportion of a se-
lected panel of circulating immune effectors specific for
tumor antigens known to be expressed in RCC and/or
melanoma.
Secondary objectives
(1)to prospectively determine the predictive value of
pretreatment biomarkers in identifying patients who
could potentially benefit from combined RT/HD-IL-2
treatment, i.e. serum levels of VEGF-A, fibronectin,
proinflammatory cytokines (IL-1beta, IL-6, IL-8, IL-10,
IL-12, alphaTNF), tumor tissue expression of CAIX for





Summary of trial design
Single center, open-label proof-of-principle phase II trial
to assess immune response and predictive biomarkers of
response.
Three daily doses of booster radiotherapy (XRT) at 6–
12 Gy to 1–5 metastatic fields will be administered on
days −4 -3 -2 or −3 -2 -1 before the first and the third
cycle of IL-2. IL-2 will be administered on day +1 of
each cycle.
Treatment with IL-2 (dose 18 MIU/m2/day in 500 cc
by continuous IV infusion for 72 hours) will start on
day +1 and will be administered every 3 weeks for up to
4 cycles, then every 3–4 weeks for a further 2 cycles.
– Total duration of the trial: 36 months:
– Enrollment period: 20 months
– Treatment: maximum of 6 cycles (5 months)
per patient– Follow-up every three months
– Step 1: 7 patients will be enrolled; on the basis of a
minimax two-stage Simon design, a 40% immune
response will preclude further study, whereas a
70% response rate will indicate that further study
is warranted. Using alfa and beta errors of 0.10,
if an immune response is observed in at least 3 of the
7 patients enrolled during the first stage, the study
will go on with:
– Step 2: recruitment of a further 12 patients.
The treatments will be considered active if an immune
response is observed in 11 out of 19 patients treated.
The analysis will be performed on an intention-to-treat
population, i.e. all patients receiving at least one cycle of
therapy.
Primary and secondary endpoints/outcome measures
The primary objective of this study will be:
– immunological efficacy, assessed by quantification
of circulating immune effectors specific for a
selected panel of tumor antigens. In particular, this
panel will include tumor antigens known to be highly
expressed in over 80% of patients with melanoma or
RCC in and whose expression must be confirmed in
tumor biopsies taken before and after at least 2 cycles.
The secondary objectives will be
– assessment of the predictive value of pretreatment
serum biomarkers in identifying patients who will
probably benefit from high-dose IL-2 based therapy.
In particular, pretreatment concentrations of VEGF,
fibronectin and proinflammatory cytokines (IL-1beta,
IL-6, IL-8, IL-10, IL-12, alphaTNF) will be evaluated
by SearchLight multiplex array analysis. Expression of
CAIX in pretreatment biopsies from RCC patients will
be evaluated by immunohistochemistry. In melanoma
patients, tumor tissue biopsied before the start of
treatment will be evaluated for the presence of N-Ras
mutations.
– toxicity, response rate and overall survival.
Patients will be evaluated every 8 weeks by computed
tomography imaging to determine the clinical response,
and every 3 months after completion of treatment until
death. The time of disease progression and the initiation
of alternative therapies will also be recorded.
Study population
Patients with metastatic melanoma or renal cell carcin-
oma with measurable disease, life expectancy of at least
3 months and with tissue sample availability.
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1) Patients must have histologically or cytologically
confirmed non resectable stage III or IV advanced
melanoma or renal cell carcinoma (RCC).
2) Patients must have a minimum of two lesions,
one of which must be measurable (i.e. a lesion
that can be accurately measured in at least one
dimension with longest diameter >20 mm using
conventional techniques or >10 mm using spiral
CT scan).
3) At least one tumor lesion accessible for bioptic
sampling.
4) Prior lines (maximum 4) of chemotherapy,
immunotherapy or biological therapy (e.g. inhibitors
of B-Raf or c-Kit, ipilimumab, etc.) for advanced
disease are allowed (patients must have finished
prior treatments at least 4 weeks before the first
IL-2 dose).
5) Male or female, aged >18 years.
6) Life expectancy > 3 months.
7) ECOG performance status <1.
8) Patients must have normal organ and marrow
function:
– ECG and echocardiogram within normal
institutional limits.
Pulmonary function tests within normal
institutional limits (only to be performed in
patients with lung metastases or history of
impaired lung function).
9) No contraindication for the use of vasopressor
agents.
10) Female participants of child bearing potential and
male participants whose partner is of child bearing
potential must be willing to ensure that they or
their partner use effective contraception during the
study and for 3 months thereafter.
11) Participant is willing and able to give informed
consent for participation in the study.
Exclusion criteria
The participant may not enter the study if ANY of the
following apply:
(1) Patient with stage I or II melanoma or RCC.
(2) Patients who have had chemotherapy or
radiotherapy or immunotherapy within 4 weeks
(6 weeks for nitrosoureas or mitomycin C) prior
to entering the study or those who have not
recovered from adverse events due to agents
administered more than 4 weeks earlier.
(3) Participation in another clinical trial with any
investigational agents within 30 days prior to
study screening.(4) Patients with known brain metastases should be
excluded from this clinical trial because of their
poor prognosis and because they often develop
progressive neurologic dysfunction that would
confound the evaluation of neurologic and other
adverse events.
(5) History of allergic reactions attributed to
compounds of similar chemical or biologic
composition to IL-2 or other agents used in
the study.
(6) Any autoimmune disease which could be
exacerbated by IL-2.
(7) A medical illness requiring chronic treatments
with corticosteroids or other immunosuppressive
agents.
(8) A history of significant cardiovascular disease,
including myocardial infarction, congestive heart
failure, primary cardiac arrhythmias, angina
pectoris or cerebrovascular accident.
(9) Uncontrolled intercurrent illness including, but
not limited to, ongoing or active infection,
symptomatic congestive heart failure, unstable
angina pectoris, cardiac arrhythmia, or psychiatric
illness/social situations that would limit
compliance with study requirements.
(10) Other known malignant neoplastic diseases in the
patient’s medical history with a disease-free interval
of less than 5 years (except for previously treated
basal cell carcinoma and in situ carcinoma of the
uterine cervix).
(11) HIV-positivity, whether or not symptomatic.
Study treatment
Radiotherapy
Radiotherapy will be administered in three daily doses
of 6–12 Gy (depending on the volume and anatomic
location of irradiated lesion) to 1–5 non-index meta-
static fields. The reference isodose will be 60-70%/
isodose, with an increased dose distribution inside
the tumor. Radiotherapy techniques permitting a rapid
decrease of the dose distribution outside the target
(IMRT-IMAT) will be used. Pre-treatment XRT will
be scheduled to finish on day −2 or −1. Radiotherapy
will be performed twice, before the first and third
IL-2 cycles.
High-dose IL-2
The treatment is based on high-dose IL-2: 18 MIU/m2/
day in 500 cc administered by continuous IV infusion
over 72 hours. The administration of IL-2 will take place
on an inpatient basis. The first day of IL-2 therapy is
considered as Day +1. Treatment with IL-2 will be ad-
ministered every 3 weeks for up to 4 cycles, then every
4 weeks for a further 2 cycles.
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During the 3rd day of IL-2 infusion, the following will
be administered:
– 3 bolus/day of desametazone 4 mg;
– Ondansetron 8 mg ×2/day;
– Paracetamol 500 mg ×3/day;
– Adequate i.v. hydration.
Dose delays/modifications
NCI Common Toxicity Criteria version 4.0 (available at:
http://www.eortc.be/services/doc/ctc/CTCAE_4.03_2010-
06-14_QuickReference_5x7.pdf ) will be used. No dose
reductions of IL-2 are allowed. Dose delays within the
same cycle: IL-2 doses will be delayed on the basis of the
symptomatic recovery from the previous dose. A delay
longer than 24 hours will result in discontinuation of that
cycle of IL-2.
Study treatment modifications
Guidelines for delay or discontinuation of IL-2 are given
in Tables 1 and Table 2. The presence of relative criteria
implies that a patient is nearing the completion of a
cycle of therapy and that with appropriate corrective
measures or with a time delay to allow for recovery, it
may be safe to administer another IL-2 dose. Several
relative criteria that are not easily reversible or correct-
able are usually an indication that treatment should be
discontinued. The presence of an absolute criterion that
is not easily reversible is also generally considered an in-
dication to interrupt IL-2.
Measurement of effect
Primary endpoint/translational endpoint
Immunological efficacy Immunological efficacy will be
assessed by quantifying circulating immune effectors
that are specific for a selected panel of tumor antigens.
This panel will include tumor antigens known to be
expressed at high levels by over 80% of patients with
melanoma or RCC and whose expression will confirmed
in tumor biopsies taken before and after at least 2 cycles.
Peptide libraries fully covering the sequences of tyrosin-
ase, gp100 and Mart-1 for melanoma; 5 T4, CAIX/G250
and EGF-R for RCC; and survivin, MAGE-A3 and NY-
ESO1 for both melanoma and RCC, will be utilized to
stimulate peripheral blood mononuclear cells (PBMC)
before and after therapy in IFN-g ELISPOT assays, ac-
cording to the standard operating procedures currently
used the our Somatic Cell Therapy Laboratory.
Secondary endpoints
Predictive value of pretreatment serum biomarkers
Pretreatment concentrations of VEGF, fibronectin and of
other relevant proinflammatory cytokines will be evaluatedby SearchLight multiplex array analysis according to
the manufacturer’s instructions (FDA-validated test).
Serum sampling will be performed before each cycle to
identify whether changes in marker values found during
treatment can predict early therapy failure. The expres-
sion of CAIX in tumor tissue will be evaluated in pre-
treatment biopsies from RCC patients. In particular,
both percentage and staining intensity will be recorded
for each patient. In melanoma patients, tumor tissue re-
moved before the start of treatment will be analyzed
for the presence of N-Ras mutations.
Tumor assessment
This study will use immune-related response criteria
(irRC) [45], a further refinement of mWHO criteria, to
better document tumor response in subjects undergoing
immunotherapy (Table 3). irRC were created because
the natural history of clinical response observed in sub-
jects treated with immunological agents, such as ipilimu-
mab, differs from that observed in subjects receiving
other classes of anti-cancer agents. The main differences
between irRC criteria and traditional response criteria
are as follows:
– measurable new lesions are incorporated into the
tumor burden (e.g. added to the index lesions)
and do not define progression unless the total
measurable tumor burden increases by the
required amount (25%).
– New non-measurable lesions (including bone lesions)
are not considered progression if the total measurable
tumor burden is stable or shrinking.
– Changes in non-measurable lesions contribute only
in the definition of irCR.
– Progression of disease should be confirmed at two
consecutive timepoints.
Radiologic assessment of tumor lesions
Contrast-enhanced CT scans of the brain, neck, chest,
abdomen, pelvis and soft tissue (or MRI, if iodine
contrast is medically contraindicated, e.g. for previous
allergic reactions) will be performed for all patients
during the Screening phase and at the time of tumor
re-staging during the other study phases. CT scans of
anatomic regions other than the chest, abdomen and
pelvis must be performed in subjects in whom there
is clinical suspicion of deep soft tissue metastases, e.g.
lesions in the thigh.
Objective response or progression must be docu-
mented by the same imaging technique (CT scan or
MRI) used during the Screening phase. The presence of
progressive disease is not determined on the basis of
only on a new lesion(s) found on bone scans. However,
if bone lesions are identified at any time during the
Table 1 Guidelines for delay or discontinuation of IL-2: relative and absolute criteria
System Relative criteria Absolute criteria
Cardiac - Sinus tachycardia (120–130 beats per minutes); - Sinus tachycardia (>130 beats per minutes persists after correcting




- Elevated creatine kinase isoenzymes or troponin;
- Electrocardiogram changes of ischemia;
Dermatologic — - Moist desquamation;
Gastrointestinal - Diarrhea, up to 6 episodes/day - Diarrhea, > 6 episodes/day
- Ileus/abdominal distension; - Severe abdominal distention affecting breathing;
- Bilirubin >7 mg/dl; - Severe abdominal pain, unrelenting;
Hemodynamic - Maximum neosynephrine 1–1.5 mcg/kg/min; - Maximum neosynephrine 1.5-2 mcg/kg/min;
- Maximum neosynephrine >0.5 mcg/kg/min; - Maximum neosynephrine >0.8 mcg/kg/min;
Hemorrhagic - Guiac + sputum, emesis, stool; - Frank blood sputum, emesis, stool;
- Platelets 30,000-50,000/mm3; - Platelets <30,000/mm3;
Infections — - Strong clinical suspicion or documented;
Muscoloskeletal - Weight gain >15%;
- Extremity tightness; - Extremity paresthesias;
Neurologic - Vivid dreams; - Hallucination;
- Emotional lability; - Persistent crying;
- Mental status changes not reversible in 2 hours;
- Inability to subtract 7 s or spell “world” backwards
disorientation;
Pulmonary - Resting shortness of breath; - >4 L O2 nasal cannula for saturation >95% or 40% O2 mask for
saturation >95%;
- 3-4 L O2 nasal cannula for saturation >95%; - Moist rates involving more than half of both lung fields;
- Moist rates involving more than half of both lung fields; - Endotracheal intubation;
- Pleural effusion requiring tap or chest tube;
Renal - Urine 80–160 ml/shift; - Urine <80 ml/shift;
- Urine 10–20 ml/h; - Urine <10 ml/h;
- Creatinine 2.5-2.9 mg/dl. - Creatinine >3 mg/dl.
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performed to confirm the malignant nature of the new
findings. Complete response must be confirmed by
imaging studies showing the resolution of all meta-
static lesions. Any subject who develops an objectiveTable 2 Guidelines for delay or discontinuation of IL-2 based
on the number of assessed relative or absolute criteria
Observation category Action
Any relative criteria - Initiate corrective measure +/− delayed IL-2;
Three criteria - Initiate corrective measure +/− delayed IL-2,
stop IL-2 if not easily reversible;
Any absolute criteria - Initiate corrective measure +/− delayed IL-2,
stop IL-2 if not easily reversible.tumor response (irCR or irPR) is required to undergo
confirmatory scans no less than 4 weeks after the prior
scan in order to verify the reliability of the radiologic
finding.
Method and timing
Response will be calculated according to irRC criteria.
For the purposes of this study, after baseline tumor sta-
ging performed on the day before the first treatment
cycle, patients will be re-evaluated for response every
8 weeks during therapy and every 12 weeks during fol-
low up. Confirmatory scans will also be performed no
less than 4 weeks following initial documentation of ob-
jective response and before discontinuation of treatment
due to irPD.
Table 3 Immune-related response criteria (irRC)
Index lesions Non-index lesions New measurable lesions New non -measurable lesions % Change in tumor burden Overall irRC response
CR CR No No −100% irCR
PR Any Any Any ≥ −50% irPR
PR Any Any Any < −50% to < +25% irSD
PR Any Any Any ≥ +25% irPD
SD Any Any Any < −50% to < +25% irSD
SD Any Any Any ≥ +25% irPD
PD Any Any Any ≥ +25% irPD
SD Any Any Any < −50% to < +25% irSD
SD Any Any Any ≥ +25% irPD
PD Any Any Any ≥ +25% irPD
irRC: Immune-related response criteria; CR: Complete response; PR: Partial response; SD: Stable disease; PD: Progressive disease.
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– Immune-related major durable disease control
rate (irMDDCR): the proportion of treated subjects
showing a disease control of 24 weeks measured
from week 12, or from the date of the first overall
response of irCR or irPR, until the date of irPD or
death (whichever occurs first). For a subject who
undergoes tumor resection following disease control
but prior to disease progression, duration of disease
control will be censored at the date of the last
evaluable tumor assessment on or prior to the date
of resection. Any subject who is unevaluable for
MDDC for various reasons, e.g. censoring, lost to
follow up, not assessable or unknown tumor
assessments, will be considered a non-responder.
– Immune-related objective response rate (irORR):
the proportion of treated subjects with an immune-
related best overall response (irBOR) of confirmed
irCR or confirmed irPR.
– Immune-related time to response (irTTR): the
time from first dosing date until the measurement
criteria (using irRC) are first met for overall
response of irPR or irCR (whichever status comes
first, and provided it is subsequently confirmed).
– Immune-related duration of response (irDOR): the
time between the date on which the measurement
criteria (using irRC) are first met for an irCR or irPR
(whichever status comes first and provided it is
subsequently confirmed) and the date of irPD or death
(whichever comes first). For a subject who undergoes
tumor resection following response but prior to disease
progression, irDOR will be censored on the date of the
last evaluable TA or prior to the date of resection.
– For subjects who are still alive and have no
progressive disease, as assessed by the investigator
using irRC, irDOR will be censored on the date of
the last evaluable tumor assessment.– Immune-related progression-free survival
(irPFS): the time between the first dosing date and
the date of irPD, or date of death, whichever occurs
first (i.e. subjects who die without reported irPD will
be considered to have progressed on the date of
death). For subjects with no reported post-baseline
tumor assessment, irPFS will be censored on the day
of first dosing. For a subject who undergoes tumor
resection following disease control but prior to disease
progression, irPFS will be censored on the date of the
last evaluable tumor assessment or prior to the date of
resection. For subjects who are still alive and have no
irPD, irPFS will be censored on the date of the last
evaluable tumor assessment.
– Overall survival (OS): the time from
randomization until the date of death. For those
subjects who are still alive, OS will be censored at
the recorded last date of subject contact, and for
subjects with a missing recorded last date of
contact, OS will be censored at the last date the
subject was known to be alive.
– Immune-related time to progression (irTTP): the
time from randomization to the first date of
documented irPD (or death). Subjects without
progression will be censored at their last tumor
assessment date. Subjects without progression but
who receive additional follow-up anticancer therapy
will be censored on the date of their last tumor
assessment prior to receiving the new therapy.
Subjects with progression following additional
anticancer therapy will also be censored on the
date of their last assessment prior to receiving
the therapy.
– Death on study: any death occurring between the
date of randomisation and up to 30 days after the
end of treatment must be reported to the
Coordinating Center within 24 hours as a serious
adverse event (SAE), regardless of the relation to
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follow-up period (i.e. more than 30 days after the
last vaccine dose) need only to be reported as an SAE
if it is thought that there is a possible correlation with
the study treatment(s). All deaths must be reported




Single center, open-label proof-of-principle phase II trial
to assess immune response and biomarkers potentially
predictive of response. The primary objective of this
study will be immunological efficacy, as assessed by
quantification of circulating immune effectors specific
for a selected panel of tumor antigens. Secondary end-
points will be the predictive value of pretreatment serum
biomarkers in identifying patients who are likely to
benefit from high-dose IL-2-based therapy, toxicity, re-
sponse rate (RR) and overall survival (OS). The analysis
will be performed on an intention-to-treat population,
i.e. all patients who have received at least one cycle of
therapy. All time-dependent clinical endpoints (RR and
OS) will be estimated with the Kaplan-Meier method.
Frequency tables will be performed for all categorical
variables. Continuous variables will be presented using
mean and standard deviation or median and range.
Given the explorative intent of the study and the lim-
ited sample size, we are aware of being exposed to a high
level of false-positive results. Unless otherwise indicated,
analysis of demography and baseline characteristics will
be performed on all enrolled patients. Demographic and
laboratory results will be summarized using descriptive
statistics. The percentage of patients reporting an ad-
verse event (AE) up to 30 days after the end of HD-IL-2
treatment will be calculated with 95% confidence inter-
vals by type of AE. The overall rate of grade 3–4 related
AEs will be calculated. In addition, summary statistics of
clinically significant laboratory abnormalities will be tab-
ulated. The time of disease progression and the initiation
of new therapies will also be documented.
Sample size/accrual rate
This is a proof-of-principle trial with a minimax two-
stage design:
– Step 1: 7 patients enrolled. A 40% immune response
will preclude further study, whereas a 70% response
rate will indicate that further study is warranted.
Using alfa and beta errors of 0.10, if an immune
response is observed in at least 3 of the 7 patients
enrolled during the first stage, the study will go
on with:
– Step 2: recruitment of 12 additional patients.Treatments will be considered active if an immune re-
sponse is observed in 11 out of 19 patients treated. An
enrolment period of 20 months is planned, with an ac-
crual rate of about 1 patient per month. There are no
patient stratification factors planned.
Study approval
The protocol, informed consent and any accompanying
material provided to the patient were submitted by the
investigator to the Local Ethics Committee for review.
Approval from the Committee was obtained before start-
ing the study (EudraCT no. 2012-001786- 32).
Discussion
The development of target agents to treat melanoma
and renal cell carcinoma has partially changed the his-
tory of patients with advanced disease. VEGF axis inhibi-
tors have almost doubled the survival (from 12 to
22 months) of advanced RCC patients [46], as have
BRAF inhibitors for advanced melanoma patients in a
second-line setting [47]. However, these targeted agents
rarely induce a complete and durable response. In con-
trast, HD-IL-2 has been shown to elicit durable re-
sponses ranging from 10% to 15% in melanoma patients
and from 15% to 25% in those with RCC. Standard HD-
IL-2 administration requires hospitalization and a dedi-
cated team to monitor for capillary leak syndrome.
Although patients often usually develop a flu-like syn-
drome and severe fatigue, these side-effects resolve after
suspending the infusion, without sequelae. Toxicity from
TKI or mTOR inhibitors for RCC and from chemother-
apy, BRAF inhibitors or anti-CTLA-4 antibodies for mel-
anoma are low-grade but continuous and exert a negative
impact on quality of life. Furthermore, some toxicities
have an initially mild clinical presentation and can, if not
recognized, rapidly become severe and potentially life-
threatening events [46,48-50]. If HD-IL-2 is to remain a
component of a curative treatment strategy in patients
with metastatic melanoma or RCC [51], its therapeutic
index must be improved. Two current areas of research
into immunotherapy are the elimination of immune sup-
pression and the improvement of patient selection. Based
on our understanding of mechanisms of action, some
biomarkers of response to IL-2 could help to identify
a subset of patients who would probably benefit from
treatment.
Up to now, the majority of putative predictors of IL-2
response have been post-treatment variables, such as the
height of rebound lymphocytosis, treatment induced
thrombocytopenia, the development of autoimmune thy-
roiditis and vitiligo, and the decrease in the absolute
number and frequency of peripheral Tregs. In RCC, the
level of carboxic anhydrase IX in primary tumors has
been found to be a potentially useful pretreatment
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serum vascular endothelium growth factor (VEGF) and
fibronectin have also been identified as independent pre-
dictors of non-response and poorer overall survival.
Other analyses of pretreatment factors have correlated
IL-2 with the Cw7 phenotype and low serum levels of
IL-6 and C-reactive protein, but none have proven to
be sufficiently predictive of clinical benefit to be use-
ful in selecting candidates for IL-2 therapy [43,44].
Conclusions
As long as HD-IL-2 remains a necessary component of a
curative treatment strategy in patients with metastatic
melanoma or RCC, we must strive to improve its thera-
peutic index. Two current areas of investigation into
immunotherapy focus on the elimination of immune
suppression/regulation and the improvement in patient
selection. Based on our understanding of the mecha-
nisms of action, biomarkers of response to IL-2 might
allow us to accurately select a subset of patients who will
benefit from treatment. The main aims of this study are
to improve patient selection and reduce toxicity, whilst
also guaranteeing the same clinical benefit. In an at-
tempt to develop a more manageable and better toler-
ated therapeutic schedule it has been decided to try a
short IL-2 infusion repeated every 21 days, to add corti-
costeroids [38] to reduce the risk of capillary leak
syndrome, and to add radiotherapy to exploit the abscopal
effect [52,53].
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